At a glance

Type

Peptide / related clinical research

Regulatory context

Investigational clinical research. Publication of phase 3 results does not establish marketing authorisation or availability of a particular product.

Evidence

Published randomised trials describe defined populations and endpoints. Regulatory approval, product identity and availability are separate questions.

What it is

Retatrutide combines activity at three hormone receptors in one investigational molecule. It is distinct from the dual-receptor agonist tirzepatide. The sponsor described retatrutide as investigational in its 2026 programme updates; a trial publication is not a marketing authorisation. [1] [3]

What TRIUMPH-1 measured

The 2026 phase 3 report randomised 2,339 adults with obesity without diabetes and followed treatment for 80 weeks. Its treatment-regimen analysis reported average weight reductions of 17.6%, 23.7% and 25.0% across the trial groups, versus 3.9% with placebo. The study also examined prespecified knee-osteoarthritis and sleep-apnoea subgroups. It was funded by Eli Lilly. [1]

Why the analysis method matters

The published weight estimates account for events such as treatment discontinuation using a treatment-regimen approach. They should not be mixed with larger efficacy-estimand figures from sponsor announcements that answer a different statistical question. Neither is an individual promise or a comparison against tirzepatide. [1] [3]

Evidence in people with type 2 diabetes

TRIUMPH-2 studied adults with excess body weight and type 2 diabetes across 92 centres in eight countries. At 80 weeks, estimated weight differences versus placebo ranged from 6.9 to 13.8 percentage points across the trial groups. Gastrointestinal adverse events were more frequent with retatrutide. This population differs from TRIUMPH-1, so the percentages should not be compared as if the participants were identical. [2]

What remains uncertain

Trial manufacture, eligibility criteria and monitoring are part of the evidence. A research-market vial has not demonstrated equivalence simply by displaying the molecule name. Longer-term outcomes, tolerability and the precise scope of any future authorisation must be assessed separately. This guide does not establish Thai authorisation or Asia-wide access. [1] [2] [3]

Questions to bring to a consultation

Ask whether the discussion concerns an authorised medicine or participation in a registered trial, and what evidence applies to your circumstances. Review established alternatives and the quality of the evidence, rather than choosing solely on a headline weight-loss percentage. [1] [2]

Safety and clinical context

Gastrointestinal events were common in phase 3 research. TRIUMPH-2 also reported more hypotension and altered skin sensations with retatrutide than placebo, and treatment discontinuations occurred. These findings do not establish safety of unverified products or use outside a supervised research setting. [2]

Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.